Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5661298 | 0.91 | HTR7 (0.58) | HTR7RAB9ALMNASMN1; SMN2NPC1 | |
| SCHEMBL10798879 | 0.86 | HTR7 (0.67) | HTR7RAB9ALMNASMN1; SMN2NPC1 | |
| SCHEMBL2344935 | 0.84 | HTR7 (0.64) | HTR7RAB9ALMNASMN1; SMN2NPC1 | |
| SCHEMBL701534 | 0.84 | HTR7 (0.64) | HTR7RAB9ALMNASMN1; SMN2NPC1 | |
| SCHEMBL6848695 | 0.84 | KDM4E (0.54) | HTR7RAB9ALMNASMN1; SMN2NPC1 | |
| SCHEMBL4486844 | 0.82 | HTR7 (0.52) | HTR7RAB9ALMNASMN1; SMN2NPC1 | |
| SCHEMBL29894494 | 0.82 | HTR7 (0.52) | HTR7RAB9ALMNASMN1; SMN2NPC1 | |
| SCHEMBL30883281 | 0.82 | HTR7 (0.62) | HTR7RAB9ALMNASMN1; SMN2NPC1 | |
| SCHEMBL28912859 | 0.82 | MRGPRX4 (0.47) | HTR7RAB9ALMNASMN1; SMN2NPC1 | |
| SCHEMBL25384506 | 0.80 | HTR7 (0.40) | HTR7RAB9ALMNASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023070907-A1 | ETHERIFICATION METHOD FOR HALOGENATED PHENOL | 台州学院 | 2023-05-04 | — | — | WO | disclosed |
| CN-113896618-A | Etherification method of halogenated phenol | 台州学院 | 2022-01-07 | — | — | CN | disclosed |
| CN-101166742-B | Novel lactam compound | AJINOMOTO KK | 2011-07-13 | — | — | CN | disclosed |
| US-20110152234-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | US | disclosed |
| US-7956084-B2 | Phenyl thiophene carboxamide compounds as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| EP-1421074-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| EP-2229377-A1 | 5-ALKYL/ALKENYL-3-CYANOPYRIDINES AS KINASE INHIBITORS | Wyeth LLC (US) | 2010-09-22 | — | — | EP | disclosed |
| US-20090215829-A1 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | MORLEY ANDREW DAVID | 2009-08-27 | — | — | US | disclosed |
| US-7553868-B2 | Thiophene carboxamides as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2009-06-30 | — | — | US | disclosed |
| WO-2009076602-A1 | 5-ALKYL/ALKENYL-3-CYANOPYRIDINES AS KINASE INHIBITORS | WYETH (US) | 2009-06-18 | — | — | WO | disclosed |
| EP-1583756-A1 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | AstraZeneca AB (SE) | 2005-10-12 | — | — | EP | disclosed |
| US-20040242573-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
| CN-1541214-A | Novel compounds | — | 2004-10-27 | — | — | CN | disclosed |
| WO-2004063185-A1 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | WO | disclosed |
| EP-1421074-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| EP-1370562-A1 | THIENO[2,3-D]PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-17 | — | — | EP | disclosed |
| WO-2003095441-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2003-11-20 | — | — | WO | disclosed |
| WO-2003010158-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-02-06 | — | — | WO | disclosed |
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | HARTER WILLIAM GLEN (US) | 2003-01-02 | — | — | US | disclosed |
| WO-2002064598-A1 | THIENO'2,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215829-A1 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | RELA, NFKBIA, CSNK1E | HTR7 3100/4885RAB9A 4041/4885LMNA 3926/4885 |
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | MMP13, MMP3, MMP25 | HTR7 1799/4885RAB9A 2581/4885LMNA 1210/4885 |
| US-20040242573-A1 | Novel compounds | SULT1E1, TPMT, UGT1A1 | HTR7 1222/4885RAB9A 319/4885LMNA 3431/4885 |
| US-20110152234-A1 | Novel Compounds | CNR1, ABCG2, CNR2 | HTR7 1366/4885RAB9A 1662/4885LMNA 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.